Practice Applications for Immunotherapy in Advanced CSCC

Activity Overview

In this interactive panel of multidisciplinary experts including a dermatologist and two medical oncologists, discuss the rationale for immunotherapy in CSCC, a brief overview of mechanism of action of immunotherapy and impact on side effects as well as safety and efficacy of approved checkpoint inhibitors, and identifying patients who may benefit from immunotherapy.

1.00 CE Credit(s)
Expires: October 27, 2021

Target Audience

This activity is intended for oncology and dermatology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Delineate the safety and efficacy of immunotherapeutic agents for cutaneous squamous cell carcinoma (CSCC)
  • Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
  • Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE

Chrysalyne Schmults, MD, MSCE (Chair)

Associate Professor, Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Vice Chair, Surgical Oncology for the Department of Dermatology
Brigham and Women’s Faulkner Hospital/Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Paolo Bossi, MD

Associate Professor, Medical Oncology
University of Brescia
Brescia, Italy

Axel Hauschild, MD

Professor, Dermatology
Head, Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

Céleste Lebbe, MD, PhD

Professor, Dermatology
Head of the Oncodermatology Center
Dermatology Department
AP-HP Hôpital Saint Louis
Paris Diderot Université
INSERM U976
Paris, France